<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

qz
UCB is snapping up U.S. autoimmune biotech Candid Therapeutics for $2.2 billion

The Belgian pharma company is paying $2 billion upfront for Candid's pipeline of T-cell engagers targeting autoimmune diseases [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

thenextweb
UCB pays up to $2.2bn for Candid Therapeutics, doubling down on T-cell engagers in autoimmune disease

The Belgian pharma is buying a two-year-old San Diego biotech for $2bn upfront, the second TCE bet it has placed in months. The thesis: B-cell killers built for cancer can rewire how autoimmune diseas [...]

Match Score: 161.58

thenextweb
Cambridge biotech STORM Therapeutics raises $56M

STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by e [...]

Match Score: 54.62

venturebeat
Stanford is running 37,000 AI agents as a virtual biotech — and one of its drug designs got independently confirmed by Merck

For developers, the operating assumption has been one engineer, one agent — the model Claude Code and similar tools. At VB Transform 2026, James Zou, associate professor of biomedical data science a [...]

Match Score: 50.65

qz
Eli Lilly is buying a biotech startup for nearly $3 billion to expand into autoimmune diseases

The deal adds a pipeline targeting the antibodies behind Graves' disease, thyroid eye disease, food allergy, and other conditions [...]

Match Score: 37.73

Destination
Viking Therapeutics closer to bringing its Ozempic competitor to market

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year partnership with CordenPharma, a leading contract manufacturing firm.Read more... [...]

Match Score: 32.12

qz
Vera Therapeutics stock jumps after the FDA approved its autoimmune kidney drug

Trutakna, priced at $425,000 per year, is the first drug approved in the U.S. that targets both BAFF and APRIL proteins linked to IgA nephropathy [...]

Match Score: 30.82

Destination
A revolutionary cancer treatment could transform autoimmune disease

Researchers are testing CAR T cell therapy as a way to reset the immune system. [...]

Match Score: 29.53

thenextweb
Danish biotech Cellugy wants to replace microplastics in cosmetics

Danish biotech Cellugy has raised €8.1mn in EU funding to accelerate production of a biodegradable material designed to replace microplastics in cosmetics. The grant, awarded under the EU’s LIFE P [...]

Match Score: 28.94

thenextweb
NATO’s VC fund backs biotech startup for first time

The NATO Innovation Fund (NIF) has made its first investment in a biotechnology startup. The alliance’s VC arm announced today that it’s co-leading a $35mn Series A round for UK-based Portal Biote [...]

Match Score: 28.94